tiprankstipranks
Trending News
More News >
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP

Adaptimmune Therapeutics (ADAP) Stock Statistics & Valuation Metrics

Compare
890 Followers

Total Valuation

Adaptimmune Therapeutics has a market cap or net worth of $71.50M. The enterprise value is $1.33B.
Market Cap$71.50M
Enterprise Value$1.33B

Share Statistics

Adaptimmune Therapeutics has 265,051,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding265,051,600
Owned by Insiders47.53%
Owned by Institutions0.09%

Financial Efficiency

Adaptimmune Therapeutics’s return on equity (ROE) is -5.98 and return on invested capital (ROIC) is -38.90%.
Return on Equity (ROE)-5.98
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-38.90%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee351.84K
Profits Per Employee-139.95K
Employee Count506
Asset Turnover0.72
Inventory Turnover<0.01

Valuation Ratios

The current PE Ratio of Adaptimmune Therapeutics is -1.92. Adaptimmune Therapeutics’s PEG ratio is 0.00.
PE Ratio-1.92
PS Ratio0.00
PB Ratio17.25
Price to Fair Value11.47
Price to FCF-8.23
Price to Operating Cash Flow-9.96
PEG Ratio0.00

Income Statement

In the last 12 months, Adaptimmune Therapeutics had revenue of 178.03M and earned -70.81M in profits. Earnings per share was -0.28.
Revenue178.03M
Gross Profit177.96M
Operating Income-68.76M
Pretax Income-67.24M
Net Income-70.81M
EBITDA-52.66M
Earnings Per Share (EPS)-0.28

Cash Flow

In the last 12 months, operating cash flow was -107.86M and capital expenditures -2.36M, giving a free cash flow of -110.22M billion.
Operating Cash Flow-107.86M
Free Cash Flow-110.22M
Free Cash Flow per Share-0.42

Dividends & Yields

Adaptimmune Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.60
52-Week Price Change-73.27%
50-Day Moving Average0.27
200-Day Moving Average0.60
Relative Strength Index (RSI)45.22
Average Volume (3m)1.26M

Important Dates

Adaptimmune Therapeutics upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date

Financial Position

Adaptimmune Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 28.18%
Current Ratio2.92
Quick Ratio2.80
Debt to Market Cap0.40
Net Debt to EBITDA0.32
Interest Coverage Ratio-20.54

Taxes

In the past 12 months, Adaptimmune Therapeutics has paid 3.58M in taxes.
Income Tax3.58M
Effective Tax Rate-0.05

Enterprise Valuation

Adaptimmune Therapeutics EV to EBITDA ratio is -15.16, with an EV/FCF ratio of -10.52.
EV to Sales4.49
EV to EBITDA-15.16
EV to Free Cash Flow-10.52
EV to Operating Cash Flow-10.91

Balance Sheet

Adaptimmune Therapeutics has $59.56M in cash and marketable securities with $23.30M in debt, giving a net cash position of -$36.27M billion.
Cash & Marketable Securities$59.56M
Total Debt$23.30M
Net Cash-$36.27M
Net Cash Per Share-$0.14
Tangible Book Value Per Share<$0.01

Margins

Gross margin is -370.48%, with operating margin of -38.62%, and net profit margin of -39.78%.
Gross Margin-370.48%
Operating Margin-38.62%
Pretax Margin-37.77%
Net Profit Margin-39.78%
EBITDA Margin-29.58%
EBIT Margin-35.89%

Analyst Forecast

The average price target for Adaptimmune Therapeutics is $1.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.57
Price Target Upside481.48% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast883.05%
EPS Growth Forecast62.93%

Scores

Smart Score4
AI Score43.25
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis